GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Cyclically Adjusted Price-to-FCF

IRLAB Therapeutics AB (OSTO:IRLAB A) Cyclically Adjusted Price-to-FCF : (As of Jun. 25, 2025)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


IRLAB Therapeutics AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for IRLAB Therapeutics AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Cyclically Adjusted Price-to-FCF Chart

IRLAB Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IRLAB Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IRLAB Therapeutics AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, IRLAB Therapeutics AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

IRLAB Therapeutics AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

IRLAB Therapeutics AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, IRLAB Therapeutics AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.122/132.8245*132.8245
=0.122

Current CPI (Mar. 2025) = 132.8245.

IRLAB Therapeutics AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.000 100.541 0.000
201412 0.000 100.225 0.000
201512 0.000 100.276 0.000
201603 -0.386 100.751 -0.509
201606 -0.337 101.019 -0.443
201609 -0.296 101.138 -0.389
201612 -0.428 102.022 -0.557
201703 -0.414 102.022 -0.539
201706 -0.371 102.752 -0.480
201709 -0.299 103.279 -0.385
201712 -0.595 103.793 -0.761
201803 -0.393 103.962 -0.502
201806 -0.590 104.875 -0.747
201809 -0.087 105.679 -0.109
201812 -0.424 105.912 -0.532
201903 -0.432 105.886 -0.542
201906 -0.604 106.742 -0.752
201909 -0.563 107.214 -0.697
201912 -0.673 107.766 -0.829
202003 -0.538 106.563 -0.671
202006 -0.392 107.498 -0.484
202009 -0.617 107.635 -0.761
202012 -0.338 108.296 -0.415
202103 -0.433 108.360 -0.531
202106 -0.460 108.928 -0.561
202109 3.917 110.338 4.715
202112 -0.551 112.486 -0.651
202203 -0.640 114.825 -0.740
202206 -0.863 118.384 -0.968
202209 -0.580 122.296 -0.630
202212 -0.733 126.365 -0.770
202303 -0.806 127.042 -0.843
202306 -1.020 129.407 -1.047
202309 -0.707 130.224 -0.721
202312 -0.653 131.912 -0.658
202403 -0.737 132.205 -0.740
202406 0.002 132.716 0.002
202409 -0.132 132.304 -0.133
202412 -0.436 132.987 -0.435
202503 0.122 132.825 0.122

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IRLAB Therapeutics AB  (OSTO:IRLAB A) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


IRLAB Therapeutics AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB Business Description

Traded in Other Exchanges
N/A
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines